Company: AEMD
Filing Date: 2025-09-05
Form Type: 424B4
Source: 0001683168-25-006701
Chunk: 21

Company: AETHLON MEDICAL INC
Filing Date: 2025-09-05
Form: 424B4
Chunk 21
---
/12/24  | Owned    |
| 2024-522200     | Devices and methods for treating a viral infection       
 and symptoms thereof (Japan)                             | 04/12/24  | Owned    |
| 3235306         | Devices and methods for treating a viral infection       
 and symptoms thereof (Canada)                            | 4/11/2024 | Owned    |
| 22881946.2      | Devices and methods for treating a viral infection       
 and symptoms thereof (Europe)                            | 4/23/2024 | Owned    |
| 62025103640     | Devices and methods for treating a viral infection       
 and symptoms thereof (Hong Kong)                         | 2/18/2025 | Owned    |

Pending International Patent Applications

| APPLICATION       
 

#                 | APPLICATION                                         
 NAME                                                | FILING  
 DATE    | OWNED    
 OR       
 LICENSED |
| PCT/US2024/015614 | Removal of exosomes, ectosomes, mirnas, circulating 
 nucleic acids, and viral particles with             | 2/13/24 | Owned    |

Trademarks

| APPLICATION 
 NAME        | Countries                                        | Priority 
 Date     | OWNED       
 OR LICENSED |
| *SANSAGITTA | Madrid, Australia, Canada, the EU, UK, and India | 7/8/2021 | Owned       |

*The US Application for SANSAGITTA abandoned
on 12/2/24. It was used as the basis application for a Madrid registration, and the corresponding above-listed designated country registrations
can be converted to national applications to avoid abandonment.

Trademarks

In addition to the Tausome, Sansagitta
and Hemosagitta trademarks noted in the above table, we also have trademark registrations in the United States for Hemopurifier and Aethlon
Medical, Inc., and obtained a trademark registration in India for Hemopurifier. We also have common law trademark rights in Aethlon ADAPT™
and ELLSA™.

| 10 |

Industry & Competition

The industry for treating infectious
disease and cancer is extremely competitive, and companies developing new treatment procedures face significant capital and regulatory
challenges. As our Hemopurifier is a clinical-stage device, we have the additional challenge of establishing medical industry support,
which will be driven by treatment data resulting from human clinical studies. Should our device become market cleared by the FDA or the
regulatory body